Krystal Biotech, Inc. (KRYS)Healthcare | Biotechnology | Pittsburgh, United States | NasdaqGS
363.44 USD
-2.37
(-0.648%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 365.05 +1.61 (0.443%) ⇧ (July 13, 2026, 7:46 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:38 a.m. EDT
The long-term investment case is exceptionally strong, driven by a fortress balance sheet with minimal debt and robust cash generation, alongside impressive revenue and earnings growth rates that exceed industry norms. While the valuation is rich, the underlying business quality supports a premium price, though the recent annual contraction in the trailing anchor year warrants caution. For the short term, momentum is clearly building as the stock trades well above its moving averages and options flow indicates bullish positioning near current highs. There is no dividend income to rely on, making capital appreciation the sole driver of returns. Investors should be aware that the statistical forecast model offers low confidence, suggesting the immediate price move may be driven more by sentiment than predictive certainty. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.112549 |
| MSTL_74 | 0.115328 |
| AutoTheta | 0.125521 |
| MSTL_74_126 | 0.129470 |
| MSTL | 0.142815 |
| AutoARIMA | 0.153023 |
| MSTL_126 | 0.157918 |
Forecast horizon: 60 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 16.45 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.210 |
| Excess Kurtosis | -0.84 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.714 |
| Revenue per Share | 14.359 |
| Market Cap | 10,714,122,240 |
| Trailing P/E | 48.72 |
| Forward P/E | 35.59 |
| Beta | 0.50 |
| Profit Margins | 53.92% |
| Website | https://www.krystalbio.com |
As of July 11, 2026, 3:38 a.m. EDT: Speculators are positioning for upside continuation with call volume concentrated at strikes above the current price (380 to 420), while heavy put open interest at lower strikes (250 to 300) for later expirations suggests a defined downside floor. Implied volatility remains elevated across the board.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.4320855 |
| Address1 | 2,100 Wharton Street |
| Address2 | Suite 701 |
| All Time High | 382.535 |
| All Time Low | 8.03 |
| Ask | 372.44 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 374,520 |
| Average Daily Volume3 Month | 316,524 |
| Average Volume | 316,524 |
| Average Volume10Days | 374,520 |
| Beta | 0.497 |
| Bid | 371.0 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 43.372 |
| City | Pittsburgh |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 363.44 |
| Current Ratio | 9.459 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 367.79 |
| Day Low | 353.49 |
| Debt To Equity | 0.714 |
| Display Name | Krystal Biotech |
| Earnings Call Timestamp End | 1,777,897,800 |
| Earnings Call Timestamp Start | 1,777,897,800 |
| Earnings Growth | 0.525 |
| Earnings Quarterly Growth | 0.565 |
| Earnings Timestamp | 1,777,897,800 |
| Earnings Timestamp End | 1,785,760,200 |
| Earnings Timestamp Start | 1,785,760,200 |
| Ebitda | 180,468,000 |
| Ebitda Margins | 0.43245998 |
| Enterprise To Ebitda | 54.856 |
| Enterprise To Revenue | 23.723 |
| Enterprise Value | 9,899,829,248 |
| Eps Current Year | 8.29113 |
| Eps Forward | 10.21264 |
| Eps Trailing Twelve Months | 7.46 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 320.9559 |
| Fifty Day Average Change | 42.4841 |
| Fifty Day Average Change Percent | 0.1323674 |
| Fifty Two Week Change Percent | 143.20856 |
| Fifty Two Week High | 382.535 |
| Fifty Two Week High Change | -19.095001 |
| Fifty Two Week High Change Percent | -0.049917005 |
| Fifty Two Week Low | 130.5 |
| Fifty Two Week Low Change | 232.94 |
| Fifty Two Week Low Change Percent | 1.7849809 |
| Fifty Two Week Range | 130.5 - 382.535 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,505,914,200,000 |
| Float Shares | 23,420,192 |
| Forward Eps | 10.21264 |
| Forward P E | 35.587273 |
| Free Cashflow | 137,491,504 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 295 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.94166 |
| Gross Profits | 392,960,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.109689996 |
| Held Percent Institutions | 0.99518996 |
| Implied Shares Outstanding | 29,479,756 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. |
| Long Name | Krystal Biotech, Inc. |
| Market | us_market |
| Market Cap | 10,714,122,240 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_534062888 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 225,030,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 10,783,694,744 |
| Number Of Analyst Opinions | 9 |
| Open | 364.98 |
| Operating Cashflow | 250,278,000 |
| Operating Margins | 0.46141997 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 412 586 5830 |
| Post Market Change | 1.6099854 |
| Post Market Change Percent | 0.44298518 |
| Post Market Price | 365.05 |
| Post Market Time | 1,783,986,384 |
| Previous Close | 365.81 |
| Price Eps Current Year | 43.834797 |
| Price Hint | 2 |
| Price To Book | 8.3796 |
| Price To Sales Trailing12 Months | 25.674622 |
| Profit Margins | 0.53925 |
| Quick Ratio | 8.816 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.18182 |
| Region | US |
| Regular Market Change | -2.37 |
| Regular Market Change Percent | -0.647876 |
| Regular Market Day High | 367.79 |
| Regular Market Day Low | 353.49 |
| Regular Market Day Range | 353.49 - 367.79 |
| Regular Market Open | 364.98 |
| Regular Market Previous Close | 365.81 |
| Regular Market Price | 363.44 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 373,944 |
| Return On Assets | 0.0904 |
| Return On Equity | 0.19902 |
| Revenue Growth | 0.319 |
| Revenue Per Share | 14.359 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 29,479,756 |
| Shares Percent Shares Out | 0.1193 |
| Shares Short | 3,517,595 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,147,863 |
| Short Name | Krystal Biotech, Inc. |
| Short Percent Of Float | 0.19590001 |
| Short Ratio | 9.04 |
| Source Interval | 15 |
| State | PA |
| Symbol | KRYS |
| Target High Price | 403.0 |
| Target Low Price | 241.0 |
| Target Mean Price | 349.77777 |
| Target Median Price | 364.0 |
| Total Cash | 823,404,992 |
| Total Cash Per Share | 27.931 |
| Total Debt | 9,112,000 |
| Total Revenue | 417,304,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 7.46 |
| Trailing P E | 48.7185 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 259.18875 |
| Two Hundred Day Average Change | 104.25125 |
| Two Hundred Day Average Change Percent | 0.40222135 |
| Type Disp | Equity |
| Volume | 373,944 |
| Website | https://www.krystalbio.com |
| Zip | 15,203 |